Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert W Buchanan

Showing results (1-10 of 219) with videos related to

Pageof 22
Sort By:
The American Journal of Psychiatry|November 1, 2006
Important steps in the development of cognitive-enhancing drugs in schizophreniaRobert W Buchanan
The American Journal of Psychiatry|December 1, 2020
How Much of an Advance Is the Addition of Samidorphan to Olanzapine?Robert W Buchanan
Schizophrenia Bulletin|February 25, 2014
William T. Carpenter Jr: 35 years of clinical trialsRobert W Buchanan
Schizophrenia Bulletin|November 14, 2006
Persistent negative symptoms in schizophrenia: an overviewRobert W Buchanan
Biological Psychiatry|December 15, 2010
α7 Nicotinic receptor agonists as cognitive treatments: is less (or less often) more?Robert W Buchanan, Robert Schwarcz
The American Journal of Psychiatry|May 1, 2023
An Argument for Antipsychotic PolypharmacyRobert W Buchanan, Julie Kreyenbuhl
The American Journal of Psychiatry|October 30, 2004
Prefrontal cortex, structural analysis: segmenting the prefrontal cortexRobert W Buchanan, Godfrey Pearlson
Psychiatric Services (Washington, D.C.)|May 3, 2008
Lessons to take home from CATIEWilliam T Carpenter, Robert W Buchanan
JAMA Psychiatry|June 25, 2015
Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With SchizophreniaWilliam T Carpenter, Robert W Buchanan
Schizophrenia Bulletin|June 11, 2003
Commentary on the Soteria project: misguided therapeuticsWilliam T Carpenter, Robert W Buchanan
Pageof 22

Showing results (1-10 of 219) with videos related to

Sort By:
Pageof 22
The American Journal of Psychiatry|November 1, 2006
Important steps in the development of cognitive-enhancing drugs in schizophreniaRobert W Buchanan
The American Journal of Psychiatry|December 1, 2020
How Much of an Advance Is the Addition of Samidorphan to Olanzapine?Robert W Buchanan
Schizophrenia Bulletin|February 25, 2014
William T. Carpenter Jr: 35 years of clinical trialsRobert W Buchanan
Schizophrenia Bulletin|November 14, 2006
Persistent negative symptoms in schizophrenia: an overviewRobert W Buchanan
Biological Psychiatry|December 15, 2010
α7 Nicotinic receptor agonists as cognitive treatments: is less (or less often) more?Robert W Buchanan, Robert Schwarcz
The American Journal of Psychiatry|May 1, 2023
An Argument for Antipsychotic PolypharmacyRobert W Buchanan, Julie Kreyenbuhl
The American Journal of Psychiatry|October 30, 2004
Prefrontal cortex, structural analysis: segmenting the prefrontal cortexRobert W Buchanan, Godfrey Pearlson
Psychiatric Services (Washington, D.C.)|May 3, 2008
Lessons to take home from CATIEWilliam T Carpenter, Robert W Buchanan
JAMA Psychiatry|June 25, 2015
Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With SchizophreniaWilliam T Carpenter, Robert W Buchanan
Schizophrenia Bulletin|June 11, 2003
Commentary on the Soteria project: misguided therapeuticsWilliam T Carpenter, Robert W Buchanan
Pageof 22